Burlington and Cambridge, Massachusetts, August 6, 2019 — MilliporeSigma has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and long-term archiving. Financial details were not disclosed.
“BSSN Software and the capabilities that it brings will allow MilliporeSigma’s customers to better use and share their scientific data — the most important part of laboratory experiments,” said Jean-Charles Wirth, head of Applied Solutions at MilliporeSigma. “We acquired this company for commercial growth of the lab data management technology that BSSN provided for many years. This acquisition creates opportunity and gives MilliporeSigma a unique position in this fast-paced market.”
BSSN Software is known for developing and marketing data management and integration software that unifies data from instruments and data systems and makes them available for analyzing, processing and sharing. It collects and converts scientific data from a broad range of more than 200 lab instrument models into a single, unified format. As a middleware offering, it facilitates communication and data flow between instruments and systems, such as laboratory information management systems, electronic lab notebooks and enterprise resource planning systems. The acquisition complements MilliporeSigma’s efforts to support its customers’ digital transformation in the lab.
Since 2014, MilliporeSigma has been working with BSSN Software, which primarily served pharmaceutical and food and beverage customers and provided services to facilitate standard laboratory efforts. BSSN Software was the first company to introduce to the market a complete AnIML implementation, an open standardized XML data format for storing and sharing of experiment data. With this acquisition, MilliporeSigma is combining BSSN’s technology with its market access and laboratory domain knowledge to develop and commercialize an open and interoperable platform for laboratory data.
MilliporeSigma is committed to the continued development and support of the current BSSN Software product portfolio, its customers and partnerships, as well as an open ecosystem building on the AnIML standard and Standardization in Lab Automation.
BSSN’s employees have joined MilliporeSigma as part of its Applied Digital Lab Productivity Solutions team.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.